KLRA· Health Care› Biotechnology

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. More about the company

$13.27

+2.71% today

$1.7B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is KLRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-04-17 → 2026-10-22

S? 27w

2026-04-172026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 27w current

Total tracked: 27 weeks across 1 stage run.

KLRA among Biotechnology577th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…577	KLRAKailera Therapeutics, Inc.	—	—	+1.1%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 27

1w13w26w

Week 27, mature

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.75x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+1.1%

-25.0%

-47.1%

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 27 · Vol 0.75x

2026-10-21S—

Wk 26 · Vol 0.96x

2026-10-20S—

Wk 26 · Vol 1.44x

2026-10-19S—

Wk 26 · Vol 0.82x

2026-10-16S—

Wk 26 · Vol 1.22x

2026-10-15S—

Wk 26 · Vol 1.12x

2026-10-14S—

Wk 25 · Vol 1.27x

2026-10-13S—

Wk 25 · Vol 1.09x

2026-10-12S—

Wk 25 · Vol 1.22x

2026-10-09S—

Wk 25 · Vol 2.26x

2026-10-08S—

Wk 25 · Vol 1.62x

2026-10-07S—

Wk 24 · Vol 1.17x

Moving averages & range

50 DMA

$13.89

200 DMA

—

52W High

—

52W Low

—

5D Low

$11.25

Resistance levels (recent highs)

20d High

$13.27

60d High

$18.98

120d High

$25.09

250d High

—

Next resistance

+43.0%

to 60d High

Dividend Yield

0.00%

P/B 1.5

Kailera Therapeutics: quick answers

Which sector and industry is Kailera Therapeutics in?

Kailera Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.